Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.
Atara’s most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).
Off-the-shelf ATA188 and autologous ATA190, the Company’s T-cell immunotherapies using a complementary targeted antigen recognition technology, target specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS).
Subscribe now to stay connected on the latest T-cell immunotherapy development, business and financial updates from Atara.
Copyright Nasdaq. Minimum 15 minutes delayed.
Events & Presentations
Feb 21, 2018 at 8:00 AM EST
Feb 21, 2018 at 6:15 PM MST